Head and neck diseases

To define a more precise and personalised treatment by defining new molecular prognostic and predictive tools for patients with squamous-cell carcinoma (SCC).
To define markers of detection and prognosis of HPV-induced oropharyngeal SCC, in order to obtain an early diagnosis and personalised treatment for this group of patients.
To find treatment biomarkers for induced late toxicity, in order to prevent and treat this appropriately.
To implement the use of immunotherapy for oropharyngeal SCC.
To improve transoral head and neck surgery to lead to an improvement in quality of life, with safe results.

Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

Pinato, David J.; Zambelli, Alberto; Aguilar-Company, Juan; Bower, Mark; Sng, Christopher C. T.; Salazar, Ramon; Bertuzzi, Alexia; Brunet, Joan; Mesia, Ricard; Segui, Elia; Biello, Federica; Generali, Daniele; Grisanti, Salvatore; Rizzo, Gianpiero; Libertini, Michela; Maconi, Antonio; Harbeck, Nadia; Vincenzi, Bruno; Bertulli, Rossella; Ottaviani, Diego; Carbo, Anna; Bruna, Riccardo; Benafif, Sarah; Marrari, Andrea; Wuerstlein, Rachel; Carmona-Garcia, M. Carmen; Chopra, Neha; Tondini, Carlo; Mirallas, Oriol; Tovazzi, Valeria; Betti, Marta; Provenzano, Salvatore; Fotia, Vittoria; Cruz, Claudia Andrea; Dalla Pria, Alessia; D'Avanzo, Francesca; Evans, Joanne S.; Saoudi-Gonzalez, Nadia; Felip, Eudald; Galazi, Myria; Garcia-Fructuoso, Isabel; Lee, Alvin J. X.; Newsom-Davis, Thomas; Patriarca, Andrea; Garcia-Illescas, David; Reyes, Roxana; Dileo, Palma; Sharkey, Rachel; Wong, Yien Ning Sophia; Ferrante, Daniela; Marco-Hernandez, Javier; Sureda, Anna; Maluquer, Clara; Ruiz-Camps, Isabel; Gaidano, Gianluca; Rimassa, Lorenza; Chiudinelli, Lorenzo; Izuzquiza, Macarena; Cabirta, Alba; Franchi, Michela; Santoro, Armando; Prat, Aleix; Tabernero, Josep; Gennari, Alessandra

CANCER DISCOVERY. 2020, doi: 10.1158/2159-8290.CD-20-0773

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study

Ferris, R. L.; Haddad, R.; Even, C.; Tahara, M.; Dvorkin, M.; Ciuleanu, T. E.; Clement, P. M.; Mesia, R.; Kutukova, S.; Zholudeva, L.; Daste, A.; Caballero-Daroqui, J.; Keam, B.; Vynnychenko, I.; Lafond, C.; Shetty, J.; Mann, H.; Fan, J.; Wildsmith, S.; Morsli, N.; Fayette, J.; Licitra, L.

ANNALS OF ONCOLOGY. 2020, doi: 10.1016/j.annonc.2020.04.001

The Multidisciplinary Team (MDT) Approach and Quality of Care

Taberna, Miren; Moncayo, Francisco Gil; Jane-Salas, Enric; Antonio, Maite; Arribas, Lorena; Vilajosana, Esther; Torres, Elisabet Peralvez; Mesia, Ricard

FRONTIERS IN ONCOLOGY. 2020, doi: 10.3389/fonc.2020.00085

Epidemiology of human papillomavirus-related oropharyngeal cancer in a classically low-burden region of southern Europe

Mena, M.; Frias-Gomez, J.; Taberna, M.; Quiros, B.; Marquez, S.; Clavero, O.; Baena, A.; Lloveras, B.; Alejo, M.; Leon, X.; Garcia, J.; Mesia, R.; Bermejo, O.; Bonfill, T.; Aguila, A.; Guix, M.; Hijano, R.; Pavon, M. A.; Torres, M.; Tous, S.; Cleries, R.; Alemany, L.

SCIENTIFIC REPORTS. 2020, doi: 10.1038/s41598-020-70118-7

Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial

Fernandez-Mateos, Javier; Perez-Garcia, Jessica; Seijas-Tamayo, Raquel; Mesia, Ricard; Rubio-Casadevall, Jordi; Garcia-Giron, Carlos; Iglesias, Lara; Carral Maseda, Alberto; Adansa Klain, Juan Carlos; Taberna, Miren; Vazquez, Silvia; Asuncion Gomez, Maria; del Barco, Edel; Ocana, Alberto; Gonzalez-Sarmiento, Rogelio; Jesus Cruz-Hernandez, Juan

SCIENTIFIC REPORTS. 2020, doi: 10.1038/s41598-020-72927-2

ESTUDIO DE FASE 1 PARA EVALUAR LA SEGURIDAD, TOLERABILIDAD, FARMACOCINÉTICA Y FARMACODINÁMICA DE AMG 404, UN ANTICUERPO DE MUERTE CELULAR PROGRAMADA 1 (PD-1), EN PACIENTES CON TUMORES SÓLIDOS AVANZADOS

Oliva Bernal, Marc (Principal investigator (PI))

Funder ref.:

• 20180143

2020-2021

Estudio de fase II/III, aleatorizado, doble ciego, de diseño adaptativo, de GSK3359609 o placebo en combinación con pembrolizumab para el tratamiento en primera línea del carcinoma de células escamosas de cabeza y cuello recurrente o metastásico con expresión de PD-L1

Taberna Sanz, Miren (Principal investigator (PI))

Funder Ref.:

• 209229

2020-2021

Estudio clínico de fase 2, aleatorizado, abierto y de tres grupos para evaluar la seguridad y la eficacia de lenvatinib (E7080/MK-7902) en combinación con pembrolizumab (MK-3475) frente a la quimioterapia de referencia y lenvatinib en monoterapia en participantes con carcinoma epidermoide de cabeza y cuello recurrente/metastásico (CECC R/M) que han progresado después de un tratamiento con platino e inmunoterapia (inhibidores de PD-1/PD-L1) (LEAP-009)

Taberna Sanz, Miren (Principal investigator (PI))

Funder Reference:

• MK-7902-009

2020-2021

A PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY OF AL101 IN PATIENTS WITH ADENOID CYSTIC CARCINOMA (ACC) BEARING ACTIVATING NOTCH MUTATIONS

Oliva Bernal, Marc (Principal investigator (PI))

Funder Ref.:

• AL-ACC-01

20/6/2019 -

ESTUDIO DE FASE I PARA EVALUAR LA SEGURIDAD, LA TOLERABILIDAD Y LA EFICACIA DE VCN-01 EN COMBINACIÓN CON DURVALUMAB (MEDI4736) EN PACIENTES CON CARCINOMA DE CÉLULAS ESCAMOSAS DE CABEZA Y CUELLO RECURRENTE / METASTÁSICO.

Mesia Nin, Ricard (Principal investigator (PI))

Funder Reference:

• ICO-VCN-H&N-2018

2020-2021

Other Research Lines: The role of HPV on benign nasal disorders; TC evaluation of nasosinusal anatomy and its surgical implications; Genetic disorder and surgical treatment for patients with Rendu Osler Weber disease; Impact of body composition in head and neck cancer oncospecific treatments.